Whittier Trust Co. Reduces Amgen Stake

Institutional investor trims position in biotech giant by over a third

Apr. 17, 2026 at 1:08pm

Got story updates? Submit your updates here. ›

A highly detailed, black-and-white close-up photograph of complex, industrial banking machinery and equipment, conveying a sense of the company's financial security and institutional power.An extreme close-up of Amgen's advanced biotech manufacturing equipment reflects the company's technological prowess and institutional strength.Thousand Oaks Today

Whittier Trust Co., a prominent investment management firm, has reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 34.2% during the fourth quarter, according to a recent SEC filing. The fund now owns 47,811 shares of the medical research company's stock, down from 72,638 shares previously.

Why it matters

Amgen is one of the world's largest biotechnology companies, known for its innovative drug development and strong financial performance. Institutional investors closely monitor changes in major shareholders' positions, as these can signal shifts in market sentiment or changes in a company's outlook.

The details

In its 13F filing, Whittier Trust Co. reported selling 24,827 shares of Amgen stock during the fourth quarter. The firm's remaining 47,811 shares were valued at $15.8 million as of the end of the reporting period. Whittier Trust Co. is a respected wealth management firm based in California that oversees over $7 billion in client assets.

  • Whittier Trust Co. reduced its Amgen stake during the fourth quarter of 2025.
  • The 13F filing detailing the changes was submitted on April 17, 2026.

The players

Whittier Trust Co.

A California-based wealth management firm that oversees over $7 billion in client assets.

Amgen Inc.

A global biotechnology company focused on discovering, developing, and delivering human therapeutics to address serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

This reduction in Whittier Trust Co.'s Amgen position, while relatively small, could signal a shift in investor sentiment around the biotech sector or the company's outlook. However, Amgen remains a major holding for the firm, and its long-term fundamentals continue to be strong, suggesting the stock remains an attractive investment for institutional and retail investors alike.